^
Association details:
Biomarker:EGFR G719C
Cancer:Non Small Cell Lung Cancer
Drug:gefitinib (EGFR inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: B - Late Trials
Title:

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

Published date:
06/24/2010
Excerpt:
First-line gefitinib for patients with advanced non–small-cell lung cancer who were selected on the basis of EGFR mutations improved progression-free survival, with acceptable toxicity, as compared with standard chemotherapy.
Secondary therapy:
carboplatin + paclitaxel
DOI:
10.1056/NEJMoa0909530
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Dynamic Changes of Circulating Tumor DNA in Late Stage NSCLC Patients

Excerpt:
...- Activating EGFR mutations (G719A/C/S; Exon 19 insertion/deletion; L858R; L861Q)...
Trial ID: